Citations

Showing 10 of 108094 citations.

Relationship Between Institutional Investment in High-Value Care (HVC) Performance Improvement and Internal Medicine Residents’ Perceptions of HVC Training
Smith, Cynthia D. , Arora, Vineet M. , Zaas, Aimee K. , Halvorsen, Andrew J. , Weissman, Arlene, Wahi‐Gururaj, Sandhya , Ryskina, Kira L, Ryskina, Kira L.

Mayo Clinic

Academic Medicine | April 25, 2018 | Volume: 93 | Issue: 10 | Pages: 1517-1523

10.1097/acm.0000000000002257 | PMID 29697425 Get It

Purpose To measure the association between institutional investment in high-value care (HVC) performance improvement and resident HVC experiences. Method The authors analyzed data from two 2014 surveys assessing institutions’ investments in HVC performance improvement as reported by program directors (PDs) and residents’ perceptions of the frequency of HVC teaching, participation in HVC-focused quality improvement (QI), and views on HVC topics. The authors measured the association between institutional investment and resident-reported experiences using logistic regression, controlling for program and resident characteristics. Results The sample included 214 programs and 9,854 residents (59.3% of 361 programs, 55.2% of 17,851 residents surveyed). Most PDs (158/209; 75.6%) reported some support. Residents were more likely to report HVC discussions with faculty at least a few times weekly if they trained in programs that offered HVC-focused faculty development (odds ratio [OR] = 1.19; 95% confidence interval [CI] 1.04–1.37; P = .01), that supported such faculty development (OR = 1.21; 95% CI 1.04–1.41; P = .02), or that provided physician cost-of-care performance data (OR = 1.19; 95% CI 1.03–1.39; P = .02). Residents were more likely to report participation in HVC QI if they trained in programs with a formal HVC curriculum (OR = 1.83; 95% CI 1.48–2.27; P < .001) or with HVC-focused faculty development (OR = 1.46; 95% CI 1.15–1.85; P = .002). Conclusions Institutional investment in HVC-related faculty development and physician feedback on costs of care may increase the frequency of HVC teaching and resident participation in HVC-related QI.
WATER II (80–150 mL) procedural outcomes
Desai, Mihir , Bidair, Mo, Bhojani, Naeem , Trainer, Andrew, Arther, Andrew, Kramolowsky, Eugene V., Doumanian, Leo, Elterman, Dean , Kaufman, Ronald P., Lingeman, James E., Krambeck, Amy E. , Eure, Gregg , Badlani, Gopal , Plante, Mark , Uchio, Edward , Gin, Greg , Goldenberg, Larry , Paterson, Ryan F. , So, Alan , Humphreys, Mitch, Roehrborn, Claus, Kaplan, Steven A. , Motola, Jay , Zorn, Kevin C. , Bidair, Mohamed

Mayo Clinic

BJU International | April 25, 2018 | Volume: 123 | Issue: 1 | Pages: 106-112

10.1111/bju.14360 | PMID 29694702 Get It

Objectives To present early safety and feasibility data from a multicentre prospective study (WATER II) of aquablation in the treatment of symptomatic men with large‐volume benign prostatic hyperplasia ( BPH ). Methods Between September and December 2017, 101 men with moderate‐to‐severe BPH symptoms and prostate volume of 80–150 mL underwent aquablation in a prospective multicentre international clinical trial. Baseline demographics and standardized postoperative management variables were carefully recorded in a central independently monitored database. Surgeons answered analogue scale questionnaires on intra‐operative technical factors and postoperative management. Adverse events up to 1 month were adjudicated by an independent clinical events committee. Results The mean (range) prostate volume was 107 (80–150) mL. The mean (range) operating time was 37 (15–97) min and aquablation resection time was 8 (3–15) min. Adequate adenoma resection was achieved with a single pass in 34 patients and with additional passes in 67 patients (mean 1.8 treatment passes), all in a single operating session. Haemostasis was achieved using either a Foley balloon catheter placed in the bladder under traction ( n = 98, mean duration 18 h) or direct tamponade using a balloon inflated in the prostate fossa ( n = 3, mean duration 15 h). No patient required electrocautery for haemostasis at the time of the primary procedure. The mean length of stay after the procedure was 1.6 days (range same day to 6 days). The Clavien–Dindo grade ≥2 event rate observed at 1 month was 29.7%. Bleeding complications were recorded in 10 patients (9.9%) during the index procedure hospitalization prior to discharge, and included six (5.9%) peri‐operative transfusions. Conclusions Aquablation is feasible and safe in treating men with men with large prostates (80–150 mL). The 6‐month efficacy data are being accrued and will be presented in future publications (ClinicalTrials.gov number, NCT 03123250).
The Caenorhabditis elegans spe‐49 gene is required for fertilization and encodes a sperm‐specific transmembrane protein homologous to SPE‐42
Wilson, Luke D., Obakpolor, Omoyemwen A., Jones, Autumn M., Richie, Abigail L., Mieczkowski, Bryce D., Fall, Gabriel T., Hall, Rosine W., Rumbley, Jon N. , Kroft, Tim L.

Mayo Clinic

Molecular Reproduction and Development | April 25, 2018 | Volume: 85 | Issue: 7 | Pages: 563-578

10.1002/mrd.22992 | PMID 29693775 Get It

Fertilization, the fusion of sperm and oocyte to form a zygote, is the first and arguably the most important cell–cell interaction event in an organism’s life. Forward and reverse genetic approaches in the nematode Caenorhabditis elegans have identified many genes that are required for gametogenesis and fertilization and thus are beginning to elucidate the molecular pathways that underlie these processes. We identified an allele of the spe‐49 gene in a second filial generation (F2) mutagenesis screen for spermatogenesis‐defective (spe) mutants. Mutant worms for spe‐49 produce sperm that have normal morphology, activate to form ameboid spermatozoa, and can migrate to and maintain their position in the hermaphrodite reproductive tract but fail to fertilize oocytes. This phenotype puts spe‐49 in the spe‐9 class of late‐acting genes that function in sperm at the time of fertilization. We cloned the spe‐49 gene through a combination of deficiency mapping, transgenic rescue, and genomic sequencing. spe‐49 messenger RNA (mRNA) is enriched in male germ cells, and the complementary DNA (cDNA) encodes a predicted 772‐amino‐acid six‐pass transmembrane protein that is homologous to SPE‐42. Indeed, SPE‐49 and SPE‐42 have identical predicted membrane topology and domain structure, including a large extracellular domain with six conserved cysteine residues, a DC‐STAMP domain, and a C‐terminal cytoplasmic domain containing a C4–C4 RING finger motif. The presence of two SPE‐42 homologs in animal genomes from worms to humans suggests that these proteins are highly conserved components of the molecular apparatus required for the sperm–oocyte recognition, binding, and fusion.
Streamlining cardiopulmonary exercise testing for use as a screening and tracking tool in primary care
Kim, Chul‐Ho , Iterson, Erik H. Van , Hansen, James E. , MacCarter, Dean, Johnson, Bruce D. , MacCarter, Dean J, Van Iterson, Erik H

Mayo Clinic

Pulmonary Circulation | April 25, 2018 | Volume: 8 | Issue: 2 | Pages: 1-8

10.1177/2045894018776489 | PMID 29693481 Get It

Cardiopulmonary exercise testing (CPET) using a spectrum of different approaches demonstrates usefulness for objectively assessing patient disease severity in clinical and research settings. Still, an absence of trained specialists and/or improper data interpretation techniques can pose major limitations to the effective use of CPET for the clinical classification of patients. This study aimed to test an automated disease likelihood scoring algorithm system based on cardiopulmonary responses during a simplified step‐test protocol. For patients with heart failure (HF), pulmonary hypertension (PAH), obstructive lung disease (OLD), or restrictive lung disease (RLD), we compared patient scores stratified into one of four “silos” generated from our novel algorithm system against patient evaluations provided by expert clinicians. Patients with HF (n = 12), PAH (n = 9), OLD (n = 16), or RLD (n = 10) performed baseline pulmonary function testing followed by submaximal step‐testing. Breath‐by‐breath measures of ventilation and gas exchange, in addition to oxygen saturation and heart rate were collected continuously throughout testing. The algorithm demonstrated close alignment with patient assessments provided by clinical specialists: HF (r = 0.89, P < 0.01); PAH (r = 0.88, P < 0.01); OLD (r = 0.70, P < 0.01); and RLD (r = 0.88, P < 0.01). Furthermore, the algorithm was capable of differentiating major disease from other disease pathologies. Thus, in a clinically relevant manner, these data suggest this simplified automated disease algorithm scoring system used during step‐testing to identify the likelihood that patients have HF, PAH, OLD, or RLD closely correlates with patient assessments conducted by trained clinicians.
A quantitative risk assessment for chronic traumatic encephalopathy (CTE) in football: How public health science evaluates evidence
Finkel, Adam M. , Bieniek, Kevin F.

Mayo Clinic

Human and Ecological Risk Assessment: An International Journal | April 25, 2018 | Volume: 25 | Issue: 3 | Pages: 564-589

10.1080/10807039.2018.1456899 Get It

Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group
Kossoff, Eric H. , Zupec‐Kania, Beth, Auvin, Stéphane , Ballaban‐Gil, Karen , Bergqvist, Anna, Blackford, Robyn, Buchhalter, Jeffrey , Caraballo, Roberto , Cross, J. Helen , Dahlin, Maria , Donner, Elizabeth , Güzel, Orkide, Jehle, Rana, Klepper, Joerg , Kang, Hoon‐Chul , Lambrechts, Danielle A.J.E. , Liu, Y.M. Christiana, Nathan, Janak , Pfeifer, Heidi H., Rho, Jong M. , Scheffer, Ingrid E. , Sharma, Suvasini , Stafstrom, Carl E. , Thiele, Elizabeth A. , Turner, Zahava , Vaccarezza, María, Louw, Elles van der , Friends, Matthew's, Caraballo, Roberto H , Wirrell, Elaine C., Auvin, Stéphane , Cross, Helen J , Scheffer, Ingrid E , Nordli, Douglas R. , Veggiotti, Pierangelo , Wheless, James W. , Wirrell, Elaine , Friends, Matthew's

Mayo Clinic

Epilepsia Open | April 25, 2018 | Volume: 3 | Issue: 2 | Pages: 175-192

10.1002/epi4.12225 | PMID 29881797 Get It

Summary Ketogenic dietary therapies ( KDTs ) are established, effective nonpharmacologic treatments for intractable childhood epilepsy. For many years KDTs were implemented differently throughout the world due to lack of consistent protocols. In 2009, an expert consensus guideline for the management of children on KDT was published, focusing on topics of patient selection, pre‐ KDT counseling and evaluation, diet choice and attributes, implementation, supplementation, follow‐up, side events, and KDT discontinuation. It has been helpful in outlining a state‐of‐the‐art protocol, standardizing KDT for multicenter clinical trials, and identifying areas of controversy and uncertainty for future research. Now one decade later, the organizers and authors of this guideline present a revised version with additional authors, in order to include recent research, especially regarding other dietary treatments, clarifying indications for use, side effects during initiation and ongoing use, value of supplements, and methods of KDT discontinuation. In addition, authors completed a survey of their institution's practices, which was compared to responses from the original consensus survey, to show trends in management over the last 10 years.
Interventional management of paravalvular leak
Eleid, Mackram F. , Eleid, Mackram

Mayo Clinic

Heart | April 25, 2018 | Volume: 104 | Issue: 21 | Pages: 1797-1802

10.1136/heartjnl-2017-312454 | PMID 29695513 Get It

Unrecognized lipomatosis of the femoral nerve and nerve‐territory overgrowth
Marek, Tomáš , Howe, B. Matthew, Amrami, Kimberly K. , Taunton, Michael J. , Spinner, Robert J. , Taunton, Michael J

Mayo Clinic

Clinical Anatomy | April 25, 2018 | Volume: 31 | Issue: 8 | Pages: 1210-1214

10.1002/ca.23190 | PMID 29693277 Get It

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Chuk, Meredith K. , Widemann, Brigitte C. , Liu, Xiaowei , Bernhardt, M. Brooke , Kudgus, Rachel A. , Voss, Stephan D. , Blaney, Susan M. , Fox, Elizabeth , Weigel, Brenda J. , Bernhardt, Melanie Brooke , Reid, Joel M. , Voss, Stephan D , Minard, Charles G. , Kim, AeRang

Mayo Clinic

Pediatric Blood & Cancer | April 25, 2018 | Volume: 65 | Issue: 8 | Pages: No page available

10.1002/pbc.27077 | PMID 29693796 Get It

Abstract Background We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. Methods Patients received cabozantinib tablets on a continuous dosing schedule in a rolling‐six escalating phase 1 trial design. PK and PD studies were performed. Results Forty‐one patients, median (range) age 13 (4–18) years, received cabozantinib to achieve a weekly cumulative dose equivalent to 30 (n = 6), 40 (n = 23). or 55 (n = 12) mg/m 2 /day. At 40 mg/m 2 /d, dose‐limiting toxicities (DLTs) were palmar‐plantar erythrodysesthesia syndrome, mucositis, and elevated alanine aminotransferase, lipase, and bilirubin. At 55 mg/m 2 /d, hypertension, reversible posterior leukoencephalopathy syndrome, headache, fatigue, and proteinuria were DLTs. Frequent non‐DLTs included diarrhea, hypothyroidism, fatigue, nausea, vomiting, elevated hepatic transaminases, and proteinuria. In subsequent cycles, DLTs occurred at all dose levels. Across all dose levels, the steady‐state exposure and peak cabozantinib concentrations were similar. Four patients experienced a confirmed partial response: medullary thyroid cancer (MTC; n = 2), Wilms tumor, and clear cell sarcoma. Stable disease (>6 cycles) was seen in seven patients (MTC [n = 2], Ewing sarcoma, synovial sarcoma, alveolar soft part sarcoma, paraganglioma, and ependymoma). Conclusions A protocol‐defined MTD was not reached; DLTs and dose reductions for toxicity occurred in the first and subsequent cycles at all dose levels. Based on the toxicity profile, pharmacokinetics, and responses, the recommended dose of cabozantinib in pediatric patients with refractory solid tumors is 40 mg/m 2 /day. A phase 2 study of cabozantinib is being conducted.
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Berti, Alvise , Warner, Roscoe L., Johnson, Kent J., Schroeder, Darrell R. , Kabat, Brian, Langford, Carol A. , Hoffman, Gary S., Fervenza, Fernanado C., Kallenberg, Cees G. M., Clair, E. William St. , Brunetta, Paul , Stone, John H. , Merkel, Peter A., Cornec, Divi, Schroeder, Darrell, Berti, Alvise , Schroeder, Darrell , Cornec, Divi , Fervenza, Fernanado, Seo, Philip , Spiera, Robert , Merkel, Peter A., Specks, Ulrich , Monach, Paul A.

Mayo Clinic

Arthritis & Rheumatology | April 25, 2018 | Volume: 70 | Issue: 7 | Pages: 1114-1121

10.1002/art.40471 | PMID 29693324 Get It

ObjectiveTo evaluate circulating cytokine profiles in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV), classified by antineutrophil cytoplasmic antibody (ANCA) specificity (proteinase 3 ANCA [PR3‐ANCA] versus myeloperoxidase ANCA [MPO‐ANCA]) or by clinical diagnosis (granulomatosis with polyangiitis [GPA] versus microscopic polyangiitis [MPA]).MethodsA panel of 29 cytokines was tested in 186 patients with active AAV at inclusion into the Rituximab in AAV trial. Cytokine concentrations were compared between groups within each classification system. Multivariable analyses adjusted for age, sex, and renal insufficiency were performed, with each biomarker as a dependent variable and ANCA specificity and clinical diagnosis as explanatory variables of interest.ResultsLevels of 9 circulating cytokines (interleukin‐6 [IL‐6], granulocyte–macrophage colony‐stimulating factor [GM‐CSF], IL‐15, IL‐18, CXCL8/IL‐8, CCL‐17/thymus and activation–regulated chemokine [TARC], IL‐18 binding protein [IL‐18 BP], soluble IL‐2 receptor α [sIL‐2Rα], and nerve growth factor β [NGFβ]) were significantly higher in PR3‐AAV than MPO‐AAV, 4 cytokines (sIL6R, soluble tumor necrosis factor receptor type II [sTNFRII], neutrophil gelatinase–associated lipocalin [NGAL], and soluble intercellular adhesion molecule 1 [sICAM‐1]) were higher in MPO‐AAV than in PR3‐AAV, 6 cytokines (IL‐6, GM‐CSF, IL‐15, IL‐18, sIL‐2Rα, and NGFβ) were higher in GPA than in MPA, and 3 cytokines (osteopontin, sTNFRII, and NGAL) were higher in MPA than in GPA (all P < 0.05). For nearly all cytokines, the difference between PR3‐AAV and MPO‐AAV was larger than that between GPA and MPA. The multivariate analysis showed that 8 cytokines (IL‐15, IL‐8, IL‐18 BP, NGF‐β, sICAM‐1, TARC, osteopontin, and kidney injury molecule 1 (P < 0.05) distinguished patients with AAV better (lower P values and larger effect sizes) when grouped by ANCA specificity than by clinical diagnosis.ConclusionDistinct cytokine profiles were identified for PR3‐AAV versus MPO‐AAV and for GPA versus MPA. Differences in these circulating immune mediators are more strongly associated with ANCA specificity than with clinical diagnosis, suggesting that heterogeneity in the AAV subtypes extends beyond clinical phenotypes.